Ovarian cancer: CBR-5884 demonstrates promising antitumour effects
In assays and patient-derived organoids, the small molecule inhibitor CBR-5884 successfully treated epithelial ovarian cancer.
List view / Grid view
In assays and patient-derived organoids, the small molecule inhibitor CBR-5884 successfully treated epithelial ovarian cancer.
16 May 2024 | By Drug Target Review
In recent years, immunotherapy has emerged as a revolutionary approach in cancer treatment, harnessing the power of the immune system to combat cancer cells. This webinar will explore the latest advancements in immunotherapy research, highlighting breakthroughs, challenges, and future directions in the field. Participants will gain insights, including immune checkpoint…
Researchers identified variants in three loci that were associated with risk of triple-negative breast cancer.
Confounder control and quantitative profiling revealed misleading associations between microbial markers and colorectal cancer development.
Zymeworks’ Dr Paul Moore, Dr Raffaele Colombo and Dr Jamie Rich discuss how advancements in ADCs are redefining cancer treatment. They elucidate the innovative strategies that are being developed to improve drug stability and how personalised medicine approaches are optimising outcomes for individual cancer patients, offering new hope across several…
The mouse model provides a new understanding of the fundamental aspects of KSHV, which will enable drug and vaccine development.
Scientists found that preventing the effects of prostaglandin E2 could be an effective therapy to overcome tumour defence.
The mini-colons are topobiologically complex, can be induced to develop tumours in targeted areas and reduce the use of animal models.
A new method for a fragmentation-based identification of lipids could enable the study of cancer cells in detail not seen before.
It was discovered that targeting RAS proteins prevent cancer cells from using different signalling pathways to escape cell death.
The new films killed over 80 percent of cancer cells, reduced recurrence rates and minimised undesirable chemotherapy side effects.
Researchers have developed a new tool called ‘Uveal Melanoma Immunogenic Score’ to predict which patients will respond to adoptive therapy.
A urine-based test that detects ctDNA from HPV-positive head and neck cancers could facilitate its early detection.
In this Q&A, Ichan Mount Siani researchers Dr Diego Chowell and Dr Robert Samstein share their new insights about the associations between human leukocyte antigen (HLA) class II loci and lung cancer risk.
Although pre-targeting is still in its infancy, it has immense potential to increase state-of-the-art radioligand therapies. In this Q&A, PreTT reveals how their pre-targeted RLTs surpass traditional methods, transforming cancer treatment.